EP Patent

EP4725474A1 — A solid composition of eliglustat

Assigned to Genepharm SA · Expires 2026-04-15 · 0y expired

What this patent protects

A solid pharmaceutical composition comprising a crystalline form of eliglustat free base and a pharmaceutically acceptable excipient, wherein the composition is free of binder.

USPTO Abstract

A solid pharmaceutical composition comprising a crystalline form of eliglustat free base and a pharmaceutically acceptable excipient, wherein the composition is free of binder.

Drugs covered by this patent

Patent Metadata

Patent number
EP4725474A1
Jurisdiction
EP
Classification
—
Expires
2026-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Genepharm SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.